✦ LIBER ✦

Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration – evaluation in a clinical setting

✍ Scribed by Korb, Christina; Zwiener, Isabella; Lorenz, Katrin; Mirshahi, Alireza; Pfeiffer, Norbert; Stoffelns, Bernhard

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ranibizumab treatment for neovascular ag

✍ Michalova, K; Wickremasinghe, S S; Tan, T H; Chang, A; Harper, C A; Downie, J A; 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 273 KB

Results of One-Year's Treatment with Ran

✍ Salomon Y. Cohen; Lise Dubois; Ramin Tadayoni; Franck Fajnkuchen; Sylvia Nghiem- 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 552 KB

Retinal blood flow in response to an int

✍ Jonathan A. Micieli; Edmund Tsui; Wai-Ching Lam; Michael H. Brent; Robert G. Dev 📂 Article 📅 2011 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 282 KB

A Phase IIIb Study to Evaluate the Safet

✍ David S. Boyer; Jeffrey S. Heier; David M. Brown; Steven F. Francom; Tsontcho Ia 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 717 KB

Evaluation of the siRNA PF-04523655 vers

✍ Nguyen, Quan Dong; Schachar, Ronald A.; Nduaka, Chudy I.; Sperling, Marvin; Klam 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 601 KB

Treatment of wet age-related macular deg

✍ M.A. Muriel; B. Fatela; A. Valdivia; F. Clement 📂 Article 📅 2011 🏛 Elsevier ⚖ 716 KB